There is an osteoporotic fracture every three seconds. The estimated cost of these fractures per year in the United States is USD 52B and USD 57B in Europe, according to the National Osteoporosis Foundation and the International Osteoporosis Foundation respectively, and these costs are expected to grow exponentially with the aging population. This phenomenon is largely a result of the fact that 75% of high-risk patients are not being diagnosed, nor screened, in a timely manner. Of the patients receiving a bone mineral density (BMD) assessment, roughly 40% are incompletely diagnosed, because BMD5 can only measure quantity of bone, not quality of bone.

Medimaps Group’s TBS iNsight provides deep tech bone texture analysis related to bone micro-architecture to assess bone quality, enabling clinicians to identify patients sooner and classify their fracture risk, thus improving patient management and reducing the cost of care. It has been shown that 30% of osteopenic patients are reclassified with TBS. Their technology utilizes already acquired images and therefore does not expose the patient to additional radiation and it integrates seamlessly into the workflow.

Medimaps’ proprietary and patented technology is empowered by deep learning multi-layer approach. This technology is applied to a wide spectrum of image modalities and resolution thereby providing solutions ranging from opportunistic X-ray based screening, to patient risk profiling, and to presurgical assessment.

“This is a great moment for clinicians and their patients,” said Prof Didier Hans, CEO Medimaps. “We are dedicated to the vision of improving bone health assessment to help patients before it’s too late. Our passion is to improve patient care and to empower doctor decisions by developing innovative simple solutions to complex medical needs for the benefit of healthy aging.”

Read our interview with Prof. Didier Hans.